Over-expression of calpastatin aggravates cardiotoxicity induced by doxorubicin

Cardiovascular Research

Volumn 98, Issue 3, 2013, Pages 381-390

  Wang, Yanpeng ^a,d,e   Zheng, Dong ^b   Wei, Meng ^a   Ma, Jian ^a,d,e   Yu, Yong ^c   Chen, Ruizhen ^c   Lacefield, James C ^e,f   Xu, Huaxi ^b   Peng, Tianqing ^d,e  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b JIANGSU UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

^d LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

^e UNIVERSITY OF WESTERN ONTARIO   (Canada)

^f ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

Calpain; Calpastatin; Cardiotoxicity; Doxorubicin; Protein kinase B

Indexed keywords

CALPAIN 1; CALPAIN 2; CALPASTATIN; CASPASE 3; DOXORUBICIN; GLYCOGEN SYNTHASE KINASE 3BETA; MESSENGER RNA; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARDIOTOXICITY; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; DNA FRAGMENTATION; DOWN REGULATION; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; HEART HEMODYNAMICS; HEART INJURY; HEART MUSCLE CELL; IN VIVO STUDY; MOUSE; NEWBORN; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; WILD TYPE;

CALPAIN; CALPASTATIN; CARDIOTOXICITY; DOXORUBICIN; PROTEIN KINASE B;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CALCIUM-BINDING PROTEINS; CALPAIN; CELLS, CULTURED; CYSTEINE PROTEINASE INHIBITORS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; GLYCOGEN SYNTHASE KINASE 3; HEART DISEASES; HEMODYNAMICS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MYOCYTES, CARDIAC; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RNA, MESSENGER; TIME FACTORS; TRANSFECTION; UP-REGULATION; VENTRICULAR FUNCTION, LEFT;

EID: 84877958820     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvt048     Document Type: Article

References (48)

1. Zhang YW, Shi J, Li YJ, Wei L. Cardiomyocyte death in doxorubicin-induced cardiotoxicity. Arch Immunol Ther Exp (Warsz) 2009;57:435-445.
2. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998; 339:900-905.
3. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996;125:47-58.
4. Perrin BJ, Huttenlocher A. Calpain. Int J Biochem Cell Biol 2002;34:722-725.
5. Goll DE, Thompson VF, Li H, Wei W, Cong J. The calpain system. Physiol Rev 2003; 83:731-801.
6. Li Y, Arnold JM, Pampillo M, Babwah AV, Peng T. Taurine prevents cardiomyocyte death by inhibiting NADPH oxidase-mediated calpain activation. Free Radic Biol Med 2009;46:51-61.
7. Li Y, Feng Q, Arnold M, Peng T Calpain activation contributes to hyperglycemiainduced apoptosis in cardiomyocytes. Cardiovasc Res 2009;84:100-110.
8. Maekawa A, Lee JK, Nagaya T, Kamiya K, Yasui K, Horiba M et al. Overexpression of calpastatin by gene transfer prevents troponin I degradation and ameliorates contractile dysfunction in rat hearts subjected to ischemia/reperfusion.J Mol Cell Cardiol 2003; 35:1277-1284.
9. Peltier J, Bellocq A, Perez J, Doublier S, Dubois YC, Haymann JP et al. Calpain activation and secretion promote glomerular injury in experimental glomerulonephritis: evidence from calpastatin-transgenic mice. J Am Soc Nephrol 2006;17:3415-3423.
10. Perrin C, Ecarnot-Laubriet A, Vergely C, Rochette L. Calpain and caspase-3 inhibitors reduce infarct size and post-ischemic apoptosis in rat heart without modifying contractile recovery. Cell Mol Biol (Noisy-le-grand) 2003;49:OL497-505.
11. Khalil PN, Neuhof C, Huss R, Pollhammer M, Khalil MN, Neuhof H et al. Calpain inhibition reduces infarct size and improves global hemodynamics and left ventricular contractility in a porcine myocardial ischemia/reperfusion model. Eur J Pharmacol 2005;528:124-131.
12. Li X, Li Y, Shan L, Shen E, Chen R, Peng T. Over-expression of calpastatin inhibits calpain activation and attenuates myocardial dysfunction during endotoxaemia. Cardiovasc Res 2009;83:72-79.
13. Li Y, Ma J, Zhu H, Singh M, Hill D, Greer PA et al. Targeted inhibition of calpain reduces myocardial hypertrophy and fibrosis in mouse models of type 1 diabetes. Diabetes 2011;60:2985-2994.
14. Galvez AS, Diwan A, Odley AM, Hahn HS, Osinska H, Melendez JG et al. Cardiomyocyte degeneration with calpain deficiency reveals a critical role in protein homeostasis. Circ Res 2007;100:1071-1078.
15. Taneike M, Mizote I, Morita T, Watanabe T, Hikoso S, Yamaguchi O et al. Calpain protects the heart from hemodynamic stress. J Biol Chem 2011;286:32170-32177.
16. Jang YM, Kendaiah S, Drew B, Phillips T, Selman C, Julian D et al. Doxorubicin treatment in vivo activates caspase-12 mediated cardiac apoptosis in both male and female rats. FEBS Lett 2004;577:483-490.
17. Lim CC, Zuppinger C, Guo X, Kuster GM, Helmes M, Eppenberger HM et al. Anthra-cyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes. J Biol Chem 2004;279:8290-8299.
18. Zhu H, Yang Y, Wang Y, Li J, Schiller PW, Peng T. MicroRNA-195 promotes palmitate-induced apoptosis in cardiomyocytes by down-regulating Sirt1. Cardiovasc Res 2011;92:75-84.
19. Schluter KD, Schreiber D. Adult ventricular cardiomyocytes: isolation and culture. Methods Mol Biol 2005;290:305-314.
20. Wang S, Peng Q, Zhang J, Liu L. Na+/H+ exchanger is required for hyperglycaemia-induced endothelial dysfunction via calcium-dependent calpain. Cardiovasc Res 2008;80:255-262.
21. Hu H, Li X, Li Y, Wang L, Mehta S, Feng Q et al. Calpain-1 induces apoptosis in pulmonary microvascular endothelial cells under septic conditions. Microvasc Res 2009; 78:33-39.
22. Guttmann RP, Johnson GV. Oxidative stress inhibits calpain activity in situ.J Biol Chem 1998;273:13331-13338.
23. Casey TM, Arthur PG, Bogoyevitch MA. Necrotic death without mitochondrial dysfunction-delayed death of cardiac myocytes following oxidative stress. Biochim Biophys Acta 2007;1773:342-351.
24. Letavernier E, Perez J, Bellocq A, Mesnard L, de Castro Keller A, Haymann JP et al. Targeting the calpain/calpastatin system as a new strategy to prevent cardiovascular remodeling in angiotensin II-induced hypertension. Circ Res 2008;102:720-728.
25. Trump BF, Berezesky IK, Chang SH, Phelps PC. The pathways of cell death: oncosis, apoptosis, and necrosis. Toxicol Pathol 1997;25:82-88.
26. Fan GC, Zhou X, Wang X, Song G, Qian J, Nicolaou P et al. Heat shock protein 20 interacting with phosphorylated Akt reduces doxorubicin-triggered oxidative stress and cardiotoxicity. Circ Res 2008;103:1270-1279.
27. Negoro S, Oh H, Tone E, Kunisada K, Fujio Y, Walsh K et al. Glycoprotein 130 regulates cardiac myocyte survival in doxorubicin-induced apoptosis through phosphati-dylinositol 3-kinase/Akt phosphorylation and Bcl-xL/caspase-3 interaction. Circulation 2001;103:555-561.
28. Kim KH, Oudit GY, Backx PH. Erythropoietin protects against doxorubicin-induced cardiomyopathy via a phosphatidylinositol 3-kinase-dependent pathway. J Pharmacol Exp Ther 2008;324:160-169.
29. Miyamoto S, Purcell NH, Smith JM, Gao T, Whittaker R, Huang K et al. PHLPP-1 negatively regulates Akt activity and survival in the heart. Circ Res 2010;107:476-484.
30. Smith IJ, Dodd SL. Calpain activation causes a proteasome-dependent increase in protein degradation and inhibits the Akt signalling pathway in rat diaphragm muscle. Exp Physiol 2007;92:561-573.
31. Beltran L, Chaussade C, Vanhaesebroeck B, Cutillas PR. Calpain interacts with class IA phosphoinositide 3-kinases regulating their stability and signaling activity. Proc Natl Acad Sci USA 2011;108:16217-16222.
32. Tan Y, Wu C, De Veyra T, Greer PA. Ubiquitous calpains promote both apoptosis and survival signals in response to different cell death stimuli. J Biol Chem 2006;281: 17689-17698.
33. Youn JY, Wang T, Cai H. An ezrin/calpain/PI3K/AMPK/eNOSs1179 signaling cascade mediating VEGF-dependent endothelial nitric oxide production. Circ Res 2009;104: 50-59.
34. Fu P, Arcasoy MO. Erythropoietin protects cardiac myocytes against anthracycline-induced apoptosis. Biochem Biophys Res Commun 2007;354:372-378.
35. Li K, Sung RY, Huang WZ, Yang M, Pong NH, Lee SM et al. Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin. Circulation 2006; 113:2211-2220.
36. Zalewska T, Thompson VF, Goll DE. Effect of phosphatidylinositol and inside-out erythrocyte vesicles on autolysis of muand m-calpain from bovine skeletal muscle. Biochim Biophys Acta 2004;1693:125-133.
37. Kennett SB, Roberts JD, Olden K. Requirement of protein kinase C micro activation and calpain-mediated proteolysis for arachidonic acid-stimulated adhesion of MDA-MB-435 human mammary carcinoma cells to collagen type IV. J Biol Chem 2004;279:3300-3307.
38. Raynaud F, Jond-Necand C, Marcilhac A, Furst D, Benyamin Y. Calpain 1-gamma filamin interaction in muscle cells: a possible in situ regulation by PKC-alpha. Int J Biochem Cell Biol 2006;38:404-413.
39. Shiraha H, Glading A, Chou J, Jia Z, Wells A. Activation of m-calpain (calpain II) by epidermal growth factor is limited by protein kinase A phosphorylation of m-calpain. Mol Cell Biol 2002;22:2716-2727.
40. Carragher NO. Calpain inhibition: a therapeutic strategy targeting multiple disease states. Curr Pharm Des 2006;12:615-638.
41. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007;129: 1261-1274.
42. Maruyama S, Shibata R, Ohashi K, Ohashi T, Daida H, Walsh K et al. Adiponectin ameliorates doxorubicin-induced cardiotoxicity through Akt protein-dependent mechanism. J Biol Chem 2011;286:32790-32800.
43. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 2005;122:261-273.
44. Trotman LC, Alimonti A, Scaglioni PP, Koutcher JA, Cordon-Cardo C, Pandolfi PP. Identification of a tumour suppressor network opposing nuclear Akt function. Nature 2006;441:523-527.
45. Bertoli C, Copetti T, Lam EW, Demarchi F, Schneider C. Calpain small-1 modulates Akt/FoxO3A signaling and apoptosis through PP2A. Oncogene 2009;28:721-733.
46. Azoulay-Alfaguter I, Yaffe Y, Licht-Murava A, Urbanska M, Jaworski J, Pietrokovski S et al. Distinct molecular regulation of glycogen synthase kinase-3alpha isozyme controlled by its N-terminal region: functional role in calcium/calpain signaling. J Biol Chem 2011;286:13470-13480.
47. Storr SJ, Carragher NO, Frame MC, Parr T, Martin SG. The calpain system and cancer. Nat Rev Cancer 2011;11:364-374.
48. Leloup L, Wells A. Calpains as potential anti-cancer targets. Expert Opin Ther Targets 2011;15:309-323.